Last reviewed · How we verify
Atazanavir + Ritonavir + 2 NRTIs
Atazanavir + Ritonavir + 2 NRTIs is a Antiretroviral combination therapy (protease inhibitor + pharmacokinetic booster + nucleoside reverse transcriptase inhibitors) Small molecule drug developed by Bristol-Myers Squibb. It is currently FDA-approved for HIV-1 infection in treatment-naïve and treatment-experienced adults, HIV-1 infection in combination with other antiretroviral agents. Also known as: Reyataz.
Atazanavir inhibits HIV protease to prevent viral replication, while ritonavir boosts atazanavir levels, and the two NRTIs inhibit reverse transcriptase to block HIV DNA synthesis.
Atazanavir inhibits HIV protease to prevent viral replication, while ritonavir boosts atazanavir levels, and the two NRTIs inhibit reverse transcriptase to block HIV DNA synthesis. Used for HIV-1 infection in treatment-naïve and treatment-experienced adults, HIV-1 infection in combination with other antiretroviral agents.
At a glance
| Generic name | Atazanavir + Ritonavir + 2 NRTIs |
|---|---|
| Also known as | Reyataz |
| Sponsor | Bristol-Myers Squibb |
| Drug class | Antiretroviral combination therapy (protease inhibitor + pharmacokinetic booster + nucleoside reverse transcriptase inhibitors) |
| Target | HIV protease, HIV reverse transcriptase, cytochrome P450 (CYP3A4) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
Atazanavir is a protease inhibitor that blocks the HIV protease enzyme, preventing the cleavage of viral polyproteins necessary for infectious particle maturation. Ritonavir is a pharmacokinetic booster that inhibits cytochrome P450 metabolism, dramatically increasing atazanavir plasma concentrations and allowing for lower, more convenient dosing. The two nucleoside reverse transcriptase inhibitors (NRTIs) work synergistically by inhibiting reverse transcriptase, the enzyme that converts HIV RNA into DNA, thereby blocking early steps of viral replication.
Approved indications
- HIV-1 infection in treatment-naïve and treatment-experienced adults
- HIV-1 infection in combination with other antiretroviral agents
Common side effects
- Hyperbilirubinemia (unconjugated)
- Jaundice
- Nausea
- Diarrhea
- Headache
- Rash
- Nephrolithiasis
- Cardiac conduction abnormalities (PR prolongation)
Key clinical trials
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
- Safety and Efficacy of a Switch to Doravirine, Tenofovir, Lamivudine (MK-1439A) in Human Immunodeficiency Virus (HIV-1)-Infected Participants Virologically Suppressed on an Anti-retroviral Regimen in Combination With Two Nucleoside Reverse Transcriptase Inhibitors (MK-1439A-024) (PHASE3)
- Efficacy of Atazanavir/Ritonavir Monotherapy as Maintenance in Patients With Viral Suppression (PHASE3)
- Atazanavir Used in Combination With Other Anti-HIV Drugs in HIV-Infected Infants, Children, and Adolescents (PHASE1, PHASE2)
- Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants (PHASE3)
- Continuation of Protease-Inhibitor Based Second-Line Therapy vs. Switch to B/F/TAF in Virologically Suppressed Adults (PHASE4)
- Pharmacokinetic Study of 2 Doses of ATV/r OD + 2 NRTIs in Thai HIV-1 Infected Patients (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Atazanavir + Ritonavir + 2 NRTIs CI brief — competitive landscape report
- Atazanavir + Ritonavir + 2 NRTIs updates RSS · CI watch RSS
- Bristol-Myers Squibb portfolio CI
Frequently asked questions about Atazanavir + Ritonavir + 2 NRTIs
What is Atazanavir + Ritonavir + 2 NRTIs?
How does Atazanavir + Ritonavir + 2 NRTIs work?
What is Atazanavir + Ritonavir + 2 NRTIs used for?
Who makes Atazanavir + Ritonavir + 2 NRTIs?
Is Atazanavir + Ritonavir + 2 NRTIs also known as anything else?
What drug class is Atazanavir + Ritonavir + 2 NRTIs in?
What development phase is Atazanavir + Ritonavir + 2 NRTIs in?
What are the side effects of Atazanavir + Ritonavir + 2 NRTIs?
What does Atazanavir + Ritonavir + 2 NRTIs target?
Related
- Drug class: All Antiretroviral combination therapy (protease inhibitor + pharmacokinetic booster + nucleoside reverse transcriptase inhibitors) drugs
- Target: All drugs targeting HIV protease, HIV reverse transcriptase, cytochrome P450 (CYP3A4)
- Manufacturer: Bristol-Myers Squibb — full pipeline
- Therapeutic area: All drugs in Infectious Disease / Virology
- Indication: Drugs for HIV-1 infection in treatment-naïve and treatment-experienced adults
- Indication: Drugs for HIV-1 infection in combination with other antiretroviral agents
- Also known as: Reyataz
- Compare: Atazanavir + Ritonavir + 2 NRTIs vs similar drugs
- Pricing: Atazanavir + Ritonavir + 2 NRTIs cost, discount & access